Glenmede Investment Management, LP Protagonist Therapeutics, Inc Transaction History
Glenmede Investment Management, LP
- $20 Billion
- Q3 2025
A detailed history of Glenmede Investment Management, LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Glenmede Investment Management, LP holds 18,000 shares of PTGX stock, worth $1.52 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
18,000
Previous 21,434
16.02%
Holding current value
$1.52 Million
Previous $1.18 Billion
99.9%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding PTGX
# of Institutions
296Shares Held
66.9MCall Options Held
139KPut Options Held
40.7K-
Farallon Capital Management LLC San Francisco, CA6.2MShares$524 Million1.78% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$487 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.76MShares$487 Million5.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.26MShares$360 Million0.0% of portfolio
-
State Street Corp Boston, MA3.17MShares$268 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $4.15B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...